Abiopharma

New Form 10-K - XBiotech Inc. <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001171843-26-001561 <b>Size:</b> 6 MB

ProText Mobility Inc. (OTC: TXTM) Updates Shareholders on Strategic Developments, Liquidity, and Stock Purchases

XORTX THERAPEUTICS INC. (XRTX) Files Form 6-K

Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., The Bank of New York Mellon Corporation, and Related Parties

Обновление данных компании REFAEL ADVANCED DEFENSE SYSTEMS LTD (8 изменений)

Klarna: il presidente del CdA Michael Moritz acquista 3,47 milioni di azioni, per un valore di 50 milioni di dollari

Michael Moritz, presidente de la junta directiva de Klarna, adquiere 3,47 millones de acciones por 50 millones de dólares

Michael Moritz, Board Chair von Klarna, kauft 3,47 Millionen Aktien für 50 Millionen US-Dollar

Michael Moritz, président du conseil d’administration de Klarna, acquiert 3,47 millions d’actions pour 50 millions de dollars

AWS and Cerebras Collaboration Aims to Set a New Standard for AI Inference Speed and Performance in the Cloud

Trinseo - Trinseo Reports Fourth Quarter and Full-Year 2025 Financial Results

U.S. Global Investors Declares Continued Monthly Dividend, Highlights Readiness as Geopolitical Tensions Rise

Magnera’s Next-Generation Liquid Barrier Solution Nominated for INDEX™26 Award

Castle Biosciences - Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’si31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB